minotaurs

Pure

Fiel a Verdad
Joined
Dec 20, 2001
Posts
15,135
they're endangered. at least there won't be any new ones.

AH'n:Sen. Sam Brownback this week introduced legislation outlawing "part-human, part-animal creatures, which are created in laboratories, and blur the line between species." The bill has 20 co-sponsors, all but one of them -- Mary Landrieu -- Republicans. Minotaurs, centaurs, mermaids, and satyrs everywhere vowed to vote Democrat. No word on whether Michael Steele plans to woo these diverse human-animal populations with a combination of fried-chicken, potato salad, and young men from Athens (reportedly the Minotaur's favorite).

perhaps Brownback hasn't heard of the donkey. odd, since one of its parents is an ass, perhaps also the forbear of mr. brownback.

anyone have suggestions? personally i'd like a crocodog, who'd deal appropriately with criminal trespassers, genetically altered [also forbidden by mr. b] so as to pass on the neighbors' kids.
also, a manthon, human/python combo. effective if any unwanted persons succeed in entering the house.
 
Last edited:
What I don't get about the minotaur is that it is a carnivore with a bull's head. I think someone shoul have put a little more thought into that.
 
Noooo, save manbearpig!



On a serious note, my gramp has a heart valve from a pig. Put into him in - kind of - a laboratory. Is he an outlaw now?
 
Anyone have a count on how many cross species creatures there are in our little animal kingdom? I'd be willing to bet a lot, even if you left out the micro world.

It's amazing to me they can worry about something like this, yet the economy gets put on hold. :)
 
Donkey + ass, doesn't that equal mule, a mentally retarded, sterile beast - oh heck! We are talking about politicians.:eek:
 
correction

yes, elfin, donkey is the former 'ass'. ass (male) plus horse, gives the 'mule' a fine and useful animal.

it's patently unfair then, to compare brownback to the offspring of a donkey, or ass. he's not as smart as a mule.
 
In actuality, the Minotaur's favorite snack was a virgin. It'd starve to death today. ;)
 
That was just a female virgin, wasn't it? :confused:

Hey! I just got a plot bunny!

The term in the myth was "youths and maidens". What their sexual status really was isn't obvious, though given the behavior of the Ancient Greeks, the youths had a good chance of some same-sex encounters. The girls were kept at home until they were married off, at least the urban ones were. Out in the countryside . . . ? Who knows?
 
I always thought it was a mis- translation, ie., the description wasn't quite right.
 
The term in the myth was "youths and maidens". What their sexual status really was isn't obvious, though given the behavior of the Ancient Greeks, the youths had a good chance of some same-sex encounters. The girls were kept at home until they were married off, at least the urban ones were. Out in the countryside . . . ? Who knows?

How could they tell if the youth was a virgin? They could ask, but I've never heard of a boy man admit to the shame of virginity. :confused:
 
There might actually be a serious side to this. There are attempts to infuse human genes into other species to produce -- for example -- human insulin.

Whether this is wise or not is open to debate. Like stem cell research and cloning, genetic engineering is an area where we may not really know what we're doing.
 
There might actually be a serious side to this. There are attempts to infuse human genes into other species to produce -- for example -- human insulin.

Whether this is wise or not is open to debate. Like stem cell research and cloning, genetic engineering is an area where we may not really know what we're doing.

Human insulin is being produced by bacteria as we speak. It's much easier on the system than the old kind. The downside is that there are a number of diabetics who have been on the old-fashioned kind of insulin so long, that it's the only kind they can tolerate and the drug companies stopped making it.
 
CHAD COHEN: Yet despite decades of searching for cures, all we can do is treat the symptoms, or in rare cases, perform bone marrow transplants, which are dangerous and carry a high risk of rejection.

GEORGE DALEY: And so this is a condition that we need a new approach for.

CHAD COHEN: Lately, that new approach has involved embryonic stem cells, cells that are "pluripotent," meaning they can grow into just about any cell in the body. When they were discovered, more than a decade ago, it was thought that stem cells could fix, not just sickle cells, but the damaged cells of countless diseases: Parkinson's, diabetes, A.L.S. That's what's driven George Daley, who also heads a stem cell lab, right across the street from his patients.

GEORGE DALEY: Thinking about the potential that this has for changing the way that we not only study disease, but one day treat disease, is really very, very exciting.

CHAD COHEN: But there's a problem. Stem cells, for the most part, come from human embryos, from that time, just after sperm meets egg, when we're made up of just a few dozen cells, and the function of those cells has yet to be determined. The main sources for the embryos are I.V.F. clinics, where surplus embryos are often discarded as medical waste. Still, harvesting the stem cells destroys the embryo and for many, that's morally wrong. Others believe that holding back medical progress is also wrong.

GEORGE DALEY: Here we are, at the dawn of this whole new field, all this excitement, all this possibility, and yet we're working with one hand tied behind our back.

CHAD COHEN: But in 2007, some experiments were conducted that many believe will finally bring the fighting to an end. Japanese researcher Shinya Yamanaka figured out a way to take an ordinary skin cell from an adult, turn back its genetic clock and transform it into the equivalent of an embryonic stem cell, no embryos required. Yamanaka's motivation came when he first glimpsed human embryos under a microscope about 10 years ago.

SHINYA YAMANAKA (Gladstone Institute, University of California, San Francisco): I have two daughters. And I thought, "The differences between those small embryos and my own daughters are very small."

CHAD COHEN: The realization presented some conflict for him, since, as a physician, he believed that embryonic stem cells were his best shot at treating disease.

SHINYA YAMANAKA: To me, treating patients and saving patients is the most important thing to do. But if we can avoid the usage of human embryos, we should avoid.

CHAD COHEN: Ironically, Yamanaka had to use embryonic stem cells in order to find a way to do without them. He started by exploring one of their fundamental properties. Virtually every cell in the human body has the same D.N.A. Heart cells, liver cells, skin cells, all share the same 20,000 genes. During our development as embryos, though, different genes in different cells get switched on and off, in different ways, and that's what creates all the different types of cells in our bodies. It's called cell programming. Yamanaka believed if he could find the gene switches responsible for programming stem cells, he could flip those same switches in adult cells, like skin cells, and re-program them back to the moment before their destinies were determined.

SHINYA YAMANAKA: Each cell has at least 20,000 genes, so that means we have to find those important switches from the 20,000 candidates.

CHAD COHEN: With so many genes to choose from, so many potential combinations, the search could have been infinitely complex.

GEORGE DALEY: Yamanaka's insight was to appreciate that it was a very limited set of genes. And he set out to identify them.

CHAD COHEN: First he reduced 20,000 possible gene candidates down to 100, using on-line databases. But then, the work got harder.

SHINYA YAMANAKA: We spent, like, three years to study the function of those 100 genes.

CHAD COHEN: Were there people saying, "Give up, there's no use in this?"

SHINYA YAMANAKA: Yeah, many people told me that this is going to be very difficult. "You will fail."

CHAD COHEN: Using specially engineered mice, called knockouts, he tested each gene's ability to make pluripotent stem cells, eliminating them, one by one. After more than three years, culturing hundreds of thousands of cells, Yamanaka narrowed the gene pool down to 24 genes, and finally four. Then came the moment of truth: getting these four painstakingly selected genes to make stem cells. He took some skin cells from an adult mouse, then used a virus to insert the four genes inside them. Two weeks later the skin cells in the Petri dish had completely transformed.

SHINYA YAMANAKA: We saw cells which looked like stem cells. So it was...at the moment, you know we were very, very excited, and we were very surprised.

CHAD COHEN: Yamanaka dubbed the cells "Induced Pluripotent Stem cells," or I.P.S. cells, and found they were virtually indistinguishable from embryonic stem cells.

I can't see a difference; I wouldn't expect to be able to see a difference, but...

SHINYA YAMANAKA: No, we can't see differences either. So these embryonic stem cells and Induced Pluripotent Stem cells are indistinguishable. They are the same cells.

CHAD COHEN: It's amazing.

GEORGE DALEY: Yamanaka's experiment was bold, some might say foolhardy. I think it's the type of experiment that would be laughed out of the room in a standard peer review study section. You would never have gotten your grant funded with that experiment.

CHAD COHEN: Really?

GEORGE DALEY: And now it's probably going to win Shinya Yamanaka a Nobel Prize.

CHAD COHEN: Creating stem cells without an embryo in mice certainly made headlines in the scientific community, but less than a year later came the news that caught the world's attention. Based on Yamanaka's work, three independent scientists, James Thomson in Wisconsin, George Daley in Boston and Yamanaka, himself, transformed human skin cells into I.P.S. stem cells. It was a monumental breakthrough, and in George Daley's case, the doctor even experimented on himself.

DERMATOLOGIST: So what we're going to be doing is just obtaining a small biopsy of the skin and...

GEORGE DALEY: We have a protocol where we can have anyone walk in, roll up their sleeve...we take a very small skin biopsy, smaller than the eraser at the end of a pencil.

DERMATOLOGIST: We'll just snip this, and we're good to go.

GEORGE DALEY: Fantastic.

And those skin cells are then put right into a Petri dish, and then, within a week, all of a sudden, this huge bloom of cells appears. And then you bring into them the three or four genes that do the re-programming.

What's really remarkable is that just simply putting those genes into the cell and making them work, starts this whole process. It takes those stable, specialized skin cells and erases all the skin functions, and reactivates, enlivens the embryonic functions and turns that skin cell back into a pluripotent embryonic cell. That's really...

CHAD COHEN: Back in time, basically.

GEORGE DALEY: It's back in time, I mean, it's like a whole altered universe. I mean, it's really changed the fundamental nature of that cell.

How many times would you say you've been in the hospital your whole life?

STEPHANIE TERMITUS: I can't even say it's so many; ten times a year?

CHAD COHEN: So, how long before this technology actually helps patients like Stephanie? Well, some serious challenges will have to be overcome first.

For one thing, that virus to shovel Yamanaka's four genes into adult cells can mutate a patient's D.N.A. and cause cancer. At least one of the four genes is an actual oncogene; it definitely causes cancer. And a high percentage of the mice created with these stem cells did develop cancer. But the promise of these cells far outweighs their problems, and, as we speak, researchers around the world are figuring out how to safely use them. Late in 2007, Rudolph Jaenisch, of the Whitehead Institute at M.I.T, demonstrated a powerful application of I.P.S. cells. He used them to cure sickle cell anemia in mice. To do it, he first had to give the mice the disease.

So you were able, basically, to give the mice sickle cell disease, and use that as a model?

RUDOLPH JAENISCH (Whitehead Institute, Massachusetts Institute of Technology): Yes. These mice were highly anemic. They had just stopped growing. They were very...rather small. They wouldn't gain weight, they would die early. I mean it was...it's a very faithful model of this major human disease.

You would take then a skin cell from this mouse and re-program it to I.P.S. cells.

CHAD COHEN: Jaenisch made the stem cells using Yamanaka's same four gene switches, but this time he removed that nasty oncogene once it had done its job.

RUDOLPH JAENISCH: So now these I.P.S. cells they didn't need anymore, they didn't have that oncogene. So that was useful. And then the next thing was we repaired the genetic defect by gene targeting.

CHAD COHEN: Jaenisch targeted that single sickle cell mutation, fixed it, then prompted the stem cells to become blood cells and injected them back into the mice. Since these cells came from the very same mice, they were a perfect match; there was no chance of rejection.

RUDOLPH JAENISCH: And to our—really—delight, the blood of the mouse totally normalized, and they begin to, began to gain weight. They have lived. As far as we know, they have no problem, so that they're totally cured, these mice, from the sickle cell condition.

CHAD COHEN: So have these new stem cells made embryonic stem cells obsolete? Well, until we know for sure whether they can faithfully grow into all the different cell types, the answer is definitely no.

GEORGE DALEY: I'm not willing to concede that I.P.S. cells will ever fully replace human embryonic stem cells. The embryonic stem cell line remains the gold standard.
 
There might actually be a serious side to this. There are attempts to infuse human genes into other species to produce -- for example -- human insulin.

Whether this is wise or not is open to debate. Like stem cell research and cloning, genetic engineering is an area where we may not really know what we're doing.

Actually, to some extent, there is, but I don't think that's what Brownback and the rest were thinking of. They're just fucking weird.

But I recall about 20 years ago that pigs were being modified with human genes so they'd grow faster. What gave me pause is the possibility of transmitting kuru (laughing sickness), which has historically only been available to cannibals who ate infected human brains. If we come up with a way to make the source more universal--such as pork brains--we may have a lot more of it out there. This is very possibly not an issue in this case, but making pigs more genetically compatible with human does introduce the possibility of increased disease vectoring.
 
Back
Top